BiotechTube

VXA-G1.1-NN + VXA-G2.4-NS + VXA G1.1 NN-T + VXA G2.4 NS-T

Phase 1Active
1 views this week 0 watching💤 Quiet
Interest: 23/100
23
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Norovirus Infections

Conditions

Norovirus Infections

Trial Timeline

Mar 3, 2025 → May 1, 2026

NCT ID
NCT06944717

About VXA-G1.1-NN + VXA-G2.4-NS + VXA G1.1 NN-T + VXA G2.4 NS-T

VXA-G1.1-NN + VXA-G2.4-NS + VXA G1.1 NN-T + VXA G2.4 NS-T is a phase 1 stage product being developed by Vaxart for Norovirus Infections. The current trial status is active. This product is registered under clinical trial identifier NCT06944717. Target conditions include Norovirus Infections.

What happened to similar drugs?

0 of 1 similar drugs in Norovirus Infections were approved

Approved (0) Terminated (0) Active (1)
🔄mRNA-1403ModernaPhase 3

Hype Score Breakdown

Clinical
6
Activity
12
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06944717Phase 1Active

Competing Products

13 competing products in Norovirus Infections

See all competitors
ProductCompanyStageHype Score
mRNA-1403ModernaPhase 2
0
mRNA-1403ModernaPhase 3
0
VXA-G1.1-NN + VXA-G2.4-NS + Placebo TabletsVaxartPhase 1
19
VXA-G1.1-NN (high dose) Oral Vaccine Tablet + VXA-G1.1-NN (low dose) Oral Vaccine TabletVaxartPhase 1
19
VXA-G1.1-NNVaxartPhase 1/2
22
VXA-G1.1-NN Oral VaccineVaxartPhase 1
19
VXA-G1.1-NNVaxartPhase 1
19
Norwalk GI.1 VirusVaxartPhase 1
19
VXA-G1.1-NN + Norovirus GI.1 Norwalk Virus InoculumVaxartPhase 1/2
22
Open label Bivalent GII.4/GI.1 high dose vaccine 2×10 to the power 11 IU/dose + Bivalent GII.4/GI.1 high dose vaccine 2×10 to the power 11 IU/dose + Bivalent GII.4/GI.1 medium dose vaccine 1×10 to the power 11 IU/dose + PlaceboVaxartPhase 2
25
VXA-G1.1-NN + VXA-G2.4-NS + Placebo TabletsVaxartPhase 1
19
VXA-GI.1.NN + Placebo TabletVaxartPhase 1
19
CDI-988 + PlaceboCocrystal PharmaPhase 1/2
29